source
- From confidence to capital: Positioning biotech for the next growth cycleHow can biotechs be investor ready? Key takeaways from BIO International and DIA China 2026.
- Sanofi stops development of eczema drug amlitelimab after mixed trial resultsSanofi announced on Friday that it is halting further development of amlitelimab for atopic dermatitis, a drug it had once promoted as a potential successor to its blockbuster Dupixent. The compan…